Share This Page
Drug Price Trends for LASTACAFT
✉ Email this page to a colleague
Average Pharmacy Cost for LASTACAFT
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LASTACAFT ONCE DAILY 0.25% DRP | 00023-4291-05 | 2.84123 | ML | 2025-02-19 |
| LASTACAFT ONCE DAILY 0.25% DRP | 00023-4291-05 | 2.83821 | ML | 2024-12-18 |
| LASTACAFT ONCE DAILY 0.25% DRP | 00023-4291-05 | 2.83891 | ML | 2024-09-18 |
| LASTACAFT ONCE DAILY 0.25% DRP | 00023-4291-05 | 2.83177 | ML | 2024-07-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Lastacaft
Introduction to Lastacaft
Lastacaft, also known as alcaftadine ophthalmic solution, is a medication used to treat allergic conjunctivitis. It belongs to the class of ophthalmic antihistamines and decongestants. Here, we will delve into the market analysis and price projections for Lastacaft, considering various factors that influence its market presence.
Market Size and Growth
The global allergic conjunctivitis market, in which Lastacaft is a key player, was valued at $3.04 billion in 2023 and is projected to grow to $4.96 billion by 2032, with a Compound Annual Growth Rate (CAGR) of 5.6% from 2024 to 2032[1].
Regional Market Dynamics
The Asia Pacific region is expected to register the highest CAGR due to rising awareness, substantial improvements in healthcare expenditure, and a growing prevalence of ocular allergies. For instance, in India, the prevalence of eye allergies was estimated to be 12.22% in 2019, with higher rates in males (13.44%) compared to females (10.71%)[1].
In North America, which has a significant impact on the global market, the growing prevalence of minor illnesses and the adoption of self-medication are driving factors. The approval of Lastacaft as an over-the-counter (OTC) medication in the United States in December 2021 further boosts its market presence[3].
Competitive Landscape
The allergic conjunctivitis market is dominated by key players such as Allergan (AbbVie Inc.), Bausch & Lomb, and Alcon. Lastacaft, part of Allergan’s portfolio, is one of the widely adopted products in this segment. Other companies like Sun Pharmaceuticals and Alembic Pharmaceuticals Limited are also increasing their presence by focusing on product approvals and the launch of generic versions of existing drugs[1].
Price Analysis
The cost of Lastacaft 0.25% ophthalmic solution varies depending on the pharmacy and location. As of the current data, the price for a supply of 1 milliliter is around $12.49 for cash-paying customers. Discounts and copay cards can reduce this cost significantly, with some programs offering savings of up to 80%[5].
Impact of Over-the-Counter Switches
The switch from prescription to over-the-counter status for medications like Lastacaft is a significant driver of market growth. This shift increases accessibility and reduces the cost for consumers, as they no longer need a prescription to purchase the medication. The approval of Lastacaft as an OTC drug in the United States is expected to enhance its market share and revenue[1][3].
Self-Medication Trends
The trend towards self-medication is on the rise globally, driven by the high cost of prescription drugs and the increasing availability of OTC medications. This trend is particularly pronounced in North America, where there are over 80 classes of OTC medications available, including those for allergic conjunctivitis[3].
Product Approvals and Launches
Recent and upcoming product approvals and launches are crucial for the growth of Lastacaft and similar medications. For example, the FDA approval of Lastacaft as an OTC medication in December 2021 has expanded its market reach. Other companies are also preparing to seek FDA approvals for their OTC products, which will further drive market growth[3].
Challenges and Opportunities
Despite the positive growth projections, the market faces challenges such as the COVID-19 pandemic, which had a negative impact on the global market growth due to lockdowns and reduced visits to ophthalmologists. However, the market has recovered significantly since 2021, with new product launches and delayed treatments being addressed[1].
Future Projections
Given the current trends and market dynamics, Lastacaft is expected to continue its strong market performance. The increasing prevalence of ocular allergies, the launch of new medications, and the shift towards OTC medications are key factors driving this growth. The Asia Pacific and North American regions are expected to be significant contributors to this growth[1][3].
Key Takeaways
- Market Growth: The global allergic conjunctivitis market, including Lastacaft, is projected to grow from $3.20 billion in 2024 to $4.96 billion by 2032.
- Regional Dynamics: Asia Pacific and North America are key regions driving market growth due to increasing awareness and healthcare expenditure.
- Competitive Landscape: Lastacaft is part of a market dominated by Allergan, Bausch & Lomb, and Alcon, with other players increasing their presence through generic versions.
- Price Analysis: The cost of Lastacaft is around $12.49 per milliliter, with discounts available through various programs.
- OTC Switches: The approval of Lastacaft as an OTC medication has significantly boosted its market presence.
- Self-Medication Trends: Increasing self-medication practices, especially in North America, are driving the demand for OTC medications like Lastacaft.
Frequently Asked Questions
Q: What is Lastacaft used for? A: Lastacaft, or alcaftadine ophthalmic solution, is used to treat allergic conjunctivitis.
Q: What is the current market size of the allergic conjunctivitis market? A: The global allergic conjunctivitis market was valued at $3.04 billion in 2023.
Q: What is the projected growth rate of the allergic conjunctivitis market? A: The market is expected to grow at a CAGR of 5.6% from 2024 to 2032.
Q: Which regions are driving the growth of the allergic conjunctivitis market? A: The Asia Pacific and North America regions are expected to drive significant growth due to rising awareness and healthcare expenditure.
Q: What is the impact of the COVID-19 pandemic on the allergic conjunctivitis market? A: The pandemic had a negative impact initially but the market has recovered since 2021 with new product launches and delayed treatments being addressed.
Cited Sources
- Fortune Business Insights - Allergic Conjunctivitis Market Size, Share & Growth [2032]
- Nextmsc - Allergy Treatment Market Value Analysis & Forecast | 2024-2030
- Mordor Intelligence - Over the Counter Drugs - Market Share Analysis, Industry Trends ...
- DrugPatentWatch - LASTACAFT Drug Patent Profile
- Drugs.com - Lastacaft Prices, Coupons, Copay Cards & Patient Assistance
More… ↓
